Unlocking the potential of RNAi as a therapeutic strategy against infectious viruses: an in-silico study

[1]  M. Aida,et al.  siRNA Seed Region Is Divided into Two Functionally Different Domains in RNA Interference in Response to 2′-OMe Modifications , 2022, ACS omega.

[2]  K. Saadat.  RNAi-mediated siRNA sequences to combat the COVID-19 pandemic with the inhibition of SARS-CoV2 , 2022, Gene Reports.

[3]  Hirotaka Iwakawa,et al.  Life of RISC: Formation, action, and degradation of RNA-induced silencing complex. , 2021, Molecular cell.

[4]  R. Haag,et al.  Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence , 2021, Viruses.

[5]  Md. Ashraful Hasan,et al.  Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2 , 2021, Infection, Genetics and Evolution.

[6]  K. Luo,et al.  Developing effective siRNAs to reduce the expression of key viral genes of COVID-19 , 2021, International journal of biological sciences.

[7]  R. Joshi,et al.  Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2 , 2021, Journal of biomolecular structure & dynamics.

[8]  G. Meister,et al.  siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects , 2021, Frontiers in Plant Science.

[9]  Wendy K. Jo,et al.  The evolutionary dynamics of endemic human coronaviruses , 2021, Virus evolution.

[10]  Ashish Ranjan Sharma,et al.  Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 , 2020, Frontiers in Pharmacology.

[11]  H. Gendelman,et al.  The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections , 2020, Journal of Neuroimmune Pharmacology.

[12]  Mallikarjunachari V. N. Uppuladinne,et al.  Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2 , 2020, RSC advances.

[13]  R. Baric,et al.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.

[14]  Xiangxi Wang,et al.  Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection , 2020, Cell Reports.

[15]  Md. Imtaiyaz Hassan,et al.  Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach , 2020, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.

[16]  Ashish Ranjan Sharma,et al.  Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19 , 2020, Archives of Medical Research.

[17]  Ashish Ranjan Sharma,et al.  Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More , 2020, Archives of Medical Research.

[18]  Wei Chen,et al.  Computational Identification of Small Interfering RNA Targets in SARS-CoV-2 , 2020, Virologica Sinica.

[19]  Mohammad Kawsar Sharif Siam,et al.  A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2 , 2020, bioRxiv.

[20]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[21]  M. Pal,et al.  Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update , 2020, Cureus.

[22]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[23]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[24]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[25]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[26]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[27]  M. Sotomayor,et al.  Multidomain Convergence of Argonaute during RISC Assembly Correlates with the Formation of Internal Water Clusters. , 2019, Molecular cell.

[28]  Yuanyu Huang,et al.  Clinical advances of siRNA therapeutics , 2019, The journal of gene medicine.

[29]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[30]  T. Cheatham,et al.  Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data , 2018, J. Comput. Chem..

[31]  M. Poranen,et al.  RNA Interference as a Prospective Tool for the Control of Human Viral Infections , 2018, Front. Microbiol..

[32]  I. MacRae,et al.  Structural Foundations of RNA Silencing by Argonaute. , 2017, Journal of molecular biology.

[33]  R. Klopfleisch,et al.  Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters , 2017, Molecular therapy. Nucleic acids.

[34]  Ashish Ranjan Sharma,et al.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine , 2017, Molecular therapy. Nucleic acids.

[35]  S. Harikrishna,et al.  Probing the Binding Interactions between Chemically Modified siRNAs and Human Argonaute 2 Using Microsecond Molecular Dynamics Simulations , 2017, J. Chem. Inf. Model..

[36]  Amutha Ramaswamy,et al.  Structural Dynamics of Human Argonaute2 and Its Interaction with siRNAs Designed to Target Mutant tdp43 , 2016, Adv. Bioinformatics.

[37]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[38]  R. Klopfleisch,et al.  Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice. , 2015, The Journal of infectious diseases.

[39]  Abid Qureshi,et al.  VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses , 2013, Journal of Translational Medicine.

[40]  T. Restle,et al.  Minimal mechanistic model of siRNA-dependent target RNA slicing by recombinant human Argonaute 2 protein , 2013, Proceedings of the National Academy of Sciences.

[41]  David H. Mathews,et al.  RNAstructure: web servers for RNA secondary structure prediction and analysis , 2013, Nucleic Acids Res..

[42]  G. Morris,et al.  Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  S. Gupta,et al.  Design of potential siRNA molecules for hepatitis delta virus gene silencing , 2012, Bioinformation.

[44]  L. Babiuk,et al.  Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome , 2012, BioDrugs.

[45]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[46]  I. MacRae,et al.  The Crystal Structure of Human Argonaute2 , 2012, Science.

[47]  Julia Starega-Roslan,et al.  The Role of Dicer Protein Partners in the Processing of MicroRNA Precursors , 2011, PloS one.

[48]  Y. Akao,et al.  MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. , 2011, Cancer letters.

[49]  J. Šponer,et al.  Refinement of the Cornell et al. Nucleic Acids Force Field Based on Reference Quantum Chemical Calculations of Glycosidic Torsion Profiles , 2011, Journal of chemical theory and computation.

[50]  N. Sonenberg,et al.  Structural basis for 5′-nucleotide base-specific recognition of guide RNA by human AGO2 , 2010, Nature.

[51]  David H. Mathews,et al.  RNAstructure: software for RNA secondary structure prediction and analysis , 2010, BMC Bioinformatics.

[52]  Tomoyuki Suzuki,et al.  Baculovirus-mediated bispecific short-hairpin small-interfering RNAs have remarkable ability to cope with both influenza viruses A and B. , 2009, Oligonucleotides.

[53]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[54]  T. Tuschl,et al.  Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes , 2009, Nature.

[55]  D. Mathews,et al.  Improved RNA secondary structure prediction by maximizing expected pair accuracy. , 2009, RNA.

[56]  David H. Mathews,et al.  A sequence similar to tRNA3Lys gene is embedded in HIV-1 U3/R and promotes minus strand transfer , 2009, Nature Structural &Molecular Biology.

[57]  B. Berkhout.  Toward a Durable Anti‐HIV Gene Therapy Based on RNA Interference , 2009, Annals of the New York Academy of Sciences.

[58]  Ye Ding,et al.  A structural interpretation of the effect of GC-content on efficiency of RNA interference , 2009, BMC Bioinformatics.

[59]  J. Kurreck.  RNA Interference: From Basic Research to Therapeutic Applications , 2009, Angewandte Chemie.

[60]  T. Tuschl,et al.  Structure of the guide-strand-containing argonaute silencing complex , 2008, Nature.

[61]  Xiang-Jun Lu,et al.  3DNA: a versatile, integrated software system for the analysis, rebuilding and visualization of three-dimensional nucleic-acid structures , 2008, Nature Protocols.

[62]  Mark Johnson,et al.  NCBI BLAST: a better web interface , 2008, Nucleic Acids Res..

[63]  R. Mahato,et al.  RNAi for Treating Hepatitis B Viral Infection , 2007, Pharmaceutical Research.

[64]  A. Reynolds,et al.  A protocol for designing siRNAs with high functionality and specificity , 2007, Nature Protocols.

[65]  Xiaodong Wang,et al.  Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation , 2005, Cell.

[66]  Michael Zuker,et al.  DINAMelt web server for nucleic acid melting prediction , 2005, Nucleic Acids Res..

[67]  Volker A Erdmann,et al.  Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. , 2005, Journal of molecular biology.

[68]  J. Uney,et al.  RNA interference and the use of small interfering RNA to study gene function in mammalian systems. , 2004, Journal of molecular endocrinology.

[69]  Yi-Lin Chan,et al.  Inhibition of SARS-CoV replication by siRNA , 2004, Antiviral Research.

[70]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[71]  G. Hannon,et al.  Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity , 2004, Science.

[72]  J. M. Thomson,et al.  Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.

[73]  Michael Sattler,et al.  Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain , 2004, Nature Structural &Molecular Biology.

[74]  M. Amarzguioui,et al.  An algorithm for selection of functional siRNA sequences. , 2004, Biochemical and biophysical research communications.

[75]  Ming-Ming Zhou,et al.  Structure and conserved RNA binding of the PAZ domain , 2003, Nature.

[76]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[77]  Michael R. Rose,et al.  Variation in the reversibility of evolution , 2000, Nature.

[78]  W. Kibbe,et al.  The issue of amalgams. , 1996, Nucleic Acids Res..

[79]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[80]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[81]  Zhenzhong Zhang,et al.  Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. , 2013, Biomaterials.

[82]  C. Jorgensen,et al.  siRNA-based therapeutic approaches for rheumatic diseases , 2013, Nature Reviews Rheumatology.

[83]  P. Reich,et al.  [Letters to nature] , 1975, Nature.